Denmark is currently in a four year trial scheme for medical cannabis, a program that began on January 1, 2018. There is a small but fast-growing patient base that has adopted medical cannabis as a form of treatment.
The system is regarded by many as a model framework, balancing patient access with an emphasis on robust, applicable research.
We have a partnership with one of the few licensed Danish cannabis companies, enabling the import and distribution of Materia products across the country.
These products will be manufactured specifically for the Danish market, in accordance with domestic regulations and the needs of local patients.